Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1779534 | 0.92 | CYP11B1 (0.41) | CYP2A6ALDH1A1CA12CA2CA3 | |
| SCHEMBL10591118 | 0.83 | CA2 (0.37) | CYP2A6ALDH1A1CA12CA2CA3 | |
| SCHEMBL9778872 | 0.82 | MAOB (0.55) | MAOAMAOBRAB9A | |
| SCHEMBL9451016 | 0.81 | MEN1 (0.44) | CYP11B1CYP11B2TSHRNPC1RAB9A | |
| SCHEMBL9627406 | 0.80 | CA2 (0.39) | CYP2A6ALDH1A1CA12CA2CA3 | |
| SCHEMBL31442 | 0.80 | ALDH1A1 (0.39) | CYP2A6ALDH1A1CA12CA2CA3 | |
| SCHEMBL10451078 | 0.79 | ALDH1A1 (0.38) | CYP2A6ALDH1A1CYP11B1CYP11B2KDM1A | |
| SCHEMBL4012194 | 0.78 | GABRP (0.40) | CA12CA2CA9CA14RAB9A | |
| SCHEMBL28935583 | 0.77 | MAOA (0.39) | CYP2A6ALDH1A1CA12CA2CA3 | |
| SCHEMBL9778974 | 0.77 | MAOB (0.53) | MAOAMAOBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611120-A4 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2008-04-23 | — | — | EP | claimed |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2007-01-11 | — | — | US | claimed |
| EP-1611120-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Cortical Pty Ltd (AU) | 2006-01-04 | — | — | EP | claimed |
| WO-2004089927-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2004-10-21 | — | — | WO | claimed |
| US-12606548-B2 | Fungicidal oxadiazoles | FMC CORPORATION (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240166638-A1 | FUNGICIDAL OXADIAZOLES | FMC CORP (US) | 2024-05-23 | — | — | US | disclosed |
| CN-118047729-A | Fungicidal oxadiazoles | FMC公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-118047771-A | Fungicidal oxadiazoles | FMC公司 | 2024-05-17 | — | — | CN | disclosed |
| EP-4361150-A2 | FUNGICIDAL OXADIAZOLES AND THEIR MIXTURES | FMC Corporation (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240090503-A1 | FUNGICIDAL OXADIAZOLES AND THEIR MIXTURES | FMC CORPORATION | 2024-03-21 | — | — | US | disclosed |
| CN-110650956-B | Fungicidal oxadiazoles | FMC公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-4262396-A1 | FUNGICIDAL OXADIAZOLES AND THEIR MIXTURES | FMC CORPORATION (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-1112251-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2001-07-04 | — | — | EP | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
| WO-2000015609-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2000-03-23 | — | — | WO | disclosed |
| US-5098900-A | Reducing contractions in smooth muscles | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1992-03-24 | — | — | US | disclosed |
| EP-0186817-B1 | 3(2H)PYRIDAZINONE, PROCESS FOR ITS PREPARATION AND ANTI-ALLERGIC AGENT CONTAINING IT | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1989-08-02 | — | — | EP | disclosed |
| EP-0186817-A1 | 3(2H)pyridazinone, process for its preparation and anti-allergic agent containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1986-07-09 | — | — | EP | disclosed |
| US-RE32196-E | PROPHYLACTIC CHEMOTHERAPY OF ALLERGIC CONDITIONS | LILLY INDUSTRIES LIMITED (GB) | 1986-07-01 | — | — | US | disclosed |
| US-4259340-A | PROPHYLACTIC CHEMOTHERAPY OF ALLERGIC CONDITIONS SUCH AS ASTHMA | LILLY INDUSTRIES LIMITED (GB) | 1981-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166638-A1 | FUNGICIDAL OXADIAZOLES | OXA1L, NOX1, TH | CYP2A6 540/4885ALDH1A1 603/4885CA12 3377/4885 |
| US-12606548-B2 | Fungicidal oxadiazoles | AOC2, AOC3, MT-CO3 | CYP2A6 1749/4885ALDH1A1 2861/4885CA12 2402/4885 |
| US-20240090503-A1 | FUNGICIDAL OXADIAZOLES AND THEIR MIXTURES | NOX1, TH, NOX3 | CYP2A6 1254/4885ALDH1A1 702/4885CA12 4541/4885 |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | MIF, CCL2, CCL11 | CYP2A6 3074/4885ALDH1A1 1115/4885CA12 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.